Melphalan 200mg/m2 (MEL 200) and MEL 140/DT-PACE Are Equally Effective in Multiple Myeloma (MM), While the Latter Is Less Toxic.C-reactive proteininflammationatherosclerosisatherothrombosis cardiovascular diseaseIntravenous administration to human volunteers of a commercial preparation of recombinant human...
[2]https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple-myeloma.
The most common adverse reactions observed in at least 50% of patients with multiple myeloma treated with EVOMELA were neutrophil count decreased, white blood cell count decreased, lymphocyte count decreased, platelet count decreased, diarrhea, nausea, fatigue, hypokalemia, anemia, and vomiting. ...
The most common adverse reactions observed in at least 50% of patients with multiple myeloma treated with EVOMELA were neutrophil count decreased, white blood cell count decreased, lymphocyte count decreased, platelet count decreased, diarrhea, nausea, fatigue, hypokalemia, anemia, and vomiting. ...
June 13, 2011 (London, United Kingdom) — Contrary to expectation, progression-free survival in patients with multiple myeloma is longer in patients who receive high-dose melphalan (Alkeran, GlaxoSmithKline) and undergo autologous stem cell transplantation (ASCT) than in those treated with the ...
This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM). Oral lenalidomide (10 mg/day) was administered on days 1–...
High dose melphalan is commonly used in patients with multiple myeloma (MM). Resistance to melphalan has been linked to the ability to repair DNA damage. To test whether DNA repair inhibitors overcome resistance to melphalan and and also have a direct anti-MM effect, we tested MM cell lines ...
摘要: Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myelomaLeukemia advance online publication, April 8, 2010. doi:10.1038/leu.2010.58Authors: A Pal ...关键词: Humans Multiple Myeloma Neoplasm Recurrence, Local Disease Progression Thalidomide Melphalan ...
Effect of maintenance therapy with low-dose of melphalan on multiple myeloma was studied.Sixteen cases were treated with melphalan alone at doses of 2 mg daily from the diagnosis (4 cases), or after the remission induction therapy (12 cases).There were significant objective and subjective improve...